Plain-English answer
Payer evidence for U.S. market entry must show why a product should be covered, for whom, in which setting, and under what conditions. Payers do not simply ask whether a product works; they ask whether it is medically necessary, better than alternatives, and worth paying for.
Core strategic decision
The company must decide which evidence will support coverage, which will support payment amount, which will support prior authorization criteria, and which will persuade providers. This decision should determine the regulatory pathway, reimbursement workplan, channel model, staffing level, evidence investment, and first customer segment.
Evidence and diligence questions
Useful payer evidence includes randomized or comparative studies when feasible, real-world evidence, claims impact, pathway fit, patient selection, guideline support, and health-economic analysis. Evidence should be prepared for the relevant decision-maker rather than repurposed mechanically from China-facing development, marketing, or regulatory materials.
What payer evidence must prove
Medicare coverage turns on whether an item or service is reasonable and necessary for diagnosis or treatment and falls within a Medicare benefit category. A new technology therefore needs more than FDA authorization: it needs a coverage story, a coding story, and a payment story that match the clinical setting in which it will actually be used.
For products without a national coverage determination, coverage may be handled by Medicare Administrative Contractors through local coverage determinations. When CMS considers a national coverage analysis, evidence can include literature review, public comment, outside technology assessment, MEDCAC input, and in some cases coverage with evidence development. For Chinese companies, this makes U.S.-localized patient selection, comparator choice, outcomes, site of care, and workflow evidence central to launch planning.
Research sources
- CMS Guide for Medical Technology Companies and Other Interested Parties: Medicare coding, coverage, and payment framework for device, pharmaceutical, and biotechnology companies.
- CMS Medicare Coverage Determination Process: national and local coverage concepts, reasonable-and-necessary standard, and evidence-based review.
- CMS National Coverage Determination Process and Timeline: NCA timing, public comment, MEDCAC or technology assessment use, and coverage with evidence development.
Cross-references for readers
Use this page with CPT and HCPCS coding for Chinese healthcare companies, U.S. vs. China reimbursement, and U.S. vs. China medical device pricing. The practical sequence is evidence first, then coding fit, then coverage and payment, rather than treating reimbursement as a final sales-stage problem.
U.S. entry readiness checklist
| Question | Why it matters | Failure mode |
|---|---|---|
| What is the U.S. route to permission? | FDA pathway, establishment obligations, labeling, quality systems, and postmarket requirements define legal access. | Choosing the wrong claim or pathway and then rebuilding the dossier. |
| What is the route to payment? | Codes, coverage, payment, site of care, medical necessity, and payer policy define economic access. | Receiving authorization but lacking a reimbursable use case. |
| What is the route to trust? | Evidence, U.S. references, support, privacy, liability controls, and local accountability reduce adoption friction. | Assuming low price or China scale overcomes credibility barriers. |
Commercialization implications
A China-origin healthcare company should not treat the United States as simply a higher-priced market. It is a fragmented market where the buyer, payer, user, regulator, and risk-holder are often different organizations.
How to read the opportunity
Define the U.S. entry objective
Clarify whether the company seeks FDA authorization, reimbursement, strategic partnering, investor validation, distributor coverage, or full commercialization.
Map the U.S. decision chain
Identify the regulator, code owner, payer, hospital committee, physician champion, distributor, patient, privacy officer, and risk manager who can block adoption.
Localize proof and support
Convert China evidence, product design, documentation, service, privacy architecture, and commercial claims into U.S.-credible operating assets.